Skip to main content
. Author manuscript; available in PMC: 2021 Jan 23.
Published in final edited form as: Leukemia. 2020 Jul 23;34(12):3197–3205. doi: 10.1038/s41375-020-0987-6

Figure 1:

Figure 1:

(a) Overall survival from start of BTKi treatment. (b) Estimated cumulative incidence of non-melanoma skin cancer. (c) Estimated cumulative incidence of Richter’s syndrome. (d) Estimated cumulative incidence of other second primary malignancy. Survival and cumulative incidence depicted by solid lines with 95% confidence estimates depicted by dashed lines.